Latest News

David Stitelman, MD, has received funding from the Cystic Fibrosis Research Institute to advance his collaborative research on a novel fetal therapy approach for cystic fibrosis. Working with colleagues across pediatric pulmonology, biomedical engineering, and gene editing, his team is developing nanoparticle-based strategies to deliver gene therapies before birth—aimed at preventing organ damage that begins in utero. By combining mRNA delivery and high-fidelity gene editing, this work has the potential to move toward a one-time treatment for cystic fibrosis and establish a new paradigm for treating genetic diseases before birth.

Meet Ibolya Csecs, MD, clinical fellow (cardiovascular medicine), who aims to use advanced cardiovascular imaging to detect disease earlier and better predict patient risk.

New research suggests that cognitive traits observed in some individuals with type 1 diabetes may share underlying biological origins with the disease itself.

A recent conference brought researchers from around the world to Yale University to discuss the removal of waste proteins in the brain and on cerebral amyloid angiopathy, a brain condition which causes amyloid beta to accumulate in the brain’s blood vessels.

Find Yale Pediatrics at the 2025 Pediatric Academic Societies (PAS) Meeting in Boston, MA!

Yale Pathology will have a robust presence at the 2026 United States and Canadian Academy of Pathology Annual Meeting in San Antonio, March 21-26, as dozens of faculty members, residents, and fellows have presentations planned.

With the recent launch of HealthTech Works, Yale Ventures now has five accelerator funds focused on translating academic excellence into real-world impact.

March is National Kidney Month. We spoke with Dr. Julie Goodwin about the clinical care she provides in Pediatric Nephrology, how our kidneys keep us healthy, and symptoms families can look out for in relation to their kidney health.

Yale scientists have engineered natural killer cells that eliminate solid tumors in mouse models. The study may lead to a simpler, “off the shelf” immunotherapy for hard-to-treat cancers.